23
09/25
NEWS
Chiesi Announces Results of the Tanimilast Phase III...
Chiesi Group today announced the results of the tanimilast Phase III PILASTER clinical study in Chronic...
  • PRESS RELEASE
    Chiesi Group and Arbor Biotechnologies Announce a Global...
    Exclusive collaboration and license agreement for the development and global commercialization of Arbor’s clinical-stage...